Pharma IT ApSAktiv

Description of key activities of the companyThe company's principal activities are to provide consultancy services related to information technology, where Pharma IT ApS continued its activities within the life sciences and technology sector during 2025, supporting customers with specialised consultancy, digital and technology-enabled solutions.

Net loss totals DKK 1.068.285 against profit of DKK 18.958.741 last year. Management considers the net profit or loss for the year as expected. The company has continued its normal operating activities. There have been no individual events during the financial year of such material significance that they require mention in the management’s review. The year was characterised by continued integration within the wider ProductLife Group, operational development, and ongoing investment in systems, software platforms and delivery capabilities. Management continued to focus on operational efficiency, utilisation of resources, customer delivery and long-term sustainable growth. The Company maintained a close collaboration with other Group entities through shared operations, project delivery and intercompany support arrangements. Management considers the Company’s position within the ProductLife Group to be an important factor supporting the future development and stability of the business. Management considers the financial performance for the year to be in line with expectations considering the ongoing investments and strategic development activities undertaken during the period. A debtor insurance agreement was entered into during the year to strengthen liquidity. This means that the annual report does not show a trade receivables balance, as this is aggregated under trade payables. During the year, the Company identified a material er

Uddrag af ledelsesberetningen i den seneste årsrapport.